Cardea Bio finalizes merger-acquisition of Nanosens Innovations

Cardea Bio (formerly Nanomedical Diagnostics) has finalized its merger-acquisition of Nanosens Innovations, the creators of CRISPR-Chip technology. The deal combines Cardea's graphene biosensor infrastructure with Nanosens' CRISPR-Chip technology to develop DNA-based products.

“Cardea has announced the finalization of their merger-acquisition of Nanosens Innovations, the creators of CRISPR-Chip.”graphene-info.com

• 1 source
• graphene-info.comCardea Bio and Nanosens Innovations merger-acquisition finalized | Graphene-InfoOct 20, 2019

Summarized from public sources; check the original articles before acting on it.